Register a trial

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT05910827




Registration number
NCT05910827
Ethics application status
Date submitted
1/06/2023
Date registered
20/06/2023

Titles & IDs
Public title
Study of an Anti-HER3 Antibody, HMBD-001, With Docetaxel +/- Cetuximab in Advanced Squamous Non-small Cell Lung Cancers, and HMBD-001 + Cetuximab in Advanced Squamous Cell Cancers
Scientific title
A Phase 1b Study to Evaluate HMBD-001 in Combination With Docetaxel With or Without Cetuximab in Participants With Advanced Squamous Non-Small Cell Lung Cancers, and HMBD-001 in Combination With Cetuximab in Participants With Advanced Squamous Cell Cancers
Secondary ID [1] 0 0
HMBD-001-103
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Advanced or Metastatic Squamous Non-Small Cell Lung Cancer 0 0
Advanced Head and Neck Squamous Cell Carcinoma 0 0
Advanced Esophageal Squamous Cell Carcinoma 0 0
Cervical Squamous Cell Carcinoma 0 0
Advanced Cutaneous Squamous Cell Carcinoma 0 0
Condition category
Condition code
Cancer 0 0 0 0
Non melanoma skin cancer
Cancer 0 0 0 0
Kidney
Cancer 0 0 0 0
Lung - Mesothelioma
Cancer 0 0 0 0
Lung - Non small cell
Cancer 0 0 0 0
Lung - Small cell
Cancer 0 0 0 0
Head and neck
Cancer 0 0 0 0
Oesophageal (gullet)
Skin 0 0 0 0
Other skin conditions

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - HMBD-001
Treatment: Drugs - Docetaxel
Treatment: Drugs - Cetuximab

Experimental: Arm A - Participants receive HMBD-001 with docetaxel. This treatment arm is closed to recruitment.

Experimental: Arm B - Participants receive HMBD-001 with docetaxel plus cetuximab

Experimental: Arm C - Participants receive HMBD-001 with cetuximab


Treatment: Drugs: HMBD-001
HMBD-001 is a humanized Immunoglobulin G1 (IgG1) anti-Human Epidermal Growth Factor Receptor 3(HER3) monoclonal antibody (mAb). It is administered intravenously (IV) weekly

Treatment: Drugs: Docetaxel
Docetaxel 75 mg/m\^2 or 60 mg/m IV once every 3 weeks

Treatment: Drugs: Cetuximab
Cetuximab 400 mg/m\^2 IV loading dose, followed by 250 mg/m\^2 weekly
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Incidence and Nature of Adverse Events (AEs)
Timepoint [1] 0 0
From the time the Informed Consent Form (ICF) is signed until 30 days after last dose of study treatment
Primary outcome [2] 0 0
Objective Response Rate (ORR) by Response Evaluation Criteria In Solid Tumors (RECIST) V1.1
Timepoint [2] 0 0
Up to 24 months
Primary outcome [3] 0 0
Number of participants with dose-limiting toxicities (DLTs)
Timepoint [3] 0 0
During the first three weeks of study treatment

Eligibility
Key inclusion criteria
* Ability to understand and be willing to sign an informed consent form

* Males and females aged over 18 years (or having reached the age of majority according to local laws if the age of majority is > 18 years of age)
* Eastern Cooperative Oncology Group (ECOG) status of 0 to 1
* Arm B only: Locally advanced or metastatic squamous non-small cell lung cancer for which all available standard of care treatment options have been exhausted or refused and for which at least one lesion is measurable
* Arm C only: Advanced or metastatic sqNSCLC, HNSCC, ESCC, CSCC or cervical SCC with at least one prior line of systemic therapy,
* Have an estimated life expectancy of at least 3 months
* Participants must be willing to provide a fresh tumor biopsy sample
* Have adequate organ function
* Females must be non-pregnant and non-lactating, willing to use a highly effective method of contraception from screening until study completion or be either surgically sterile or post-menopausal
* Males must be surgically sterile, abstinent, or if engaged in sexual relations with a woman of child-bearing potential, the participant and his partner must be surgically sterile or using an acceptable, highly effective contraceptive method from screening until study completion
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Prior treatment with HMBD-001, docetaxel, cetuximab or any other agent that targets Epidermal Growth Factor Receptor (EGFR) or HER3, including pan-HER inhibitors. Prior treatment with docetaxel is allowed for Arm C

* Receipt of prior targeted therapy, including but not limited to those targeting EGFR activating mutations, ALK fusions, ROS rearrangements, RET fusions or mutations, BRAF V600E mutation, MET exon 14 skipping mutation, and/or KRAS G12C mutation
* Persistent clinically significant toxicities (Grade =2) from previous anti-cancer therapy except for Grade >2 toxicities that are considered unlikely to put the participant at an increased risk of treatment-related toxicity and/or impact the study results e.g., alopecia
* Most recent anti-cancer therapy including radiotherapy at least 4 weeks, or nitrosourea or mitomycin 3 at least 6 weeks, or 5 half-lives whichever is shorter prior to starting the assigned study treatment
* Symptomatic primary Central Nervous System (CNS) cancer or metastases unless the symptoms are stable for at least 28 days prior to the first dose of the study drug and any symptoms have returned to baseline
* Evidence of abnormal cardiac function
* History of uncontrolled allergic reactions and/or known expected hypersensitivity to the study drugs used in the treatment arm to which the participant is to be enrolled into
* Any other known active malignancy except for treated cervical intraepithelial neoplasia, or non-melanoma skin cancer
* Any uncontrolled illness or significant uncontrolled condition(s) requiring systemic treatment
* Known Human Immunodeficiency Virus (HIV) infection
* Active hepatitis B or hepatitis C infection
* Pregnant or breast feeding
* COVID 19 infection within 3 months prior to the first dose of the study drug
* COVID 19 vaccination within 14 days prior to the first dose of the study drug
* Treatment with strong inhibitors or inducers of CYP3A4

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 1
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
5/02/2024
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/03/2026
Actual
Sample size
Target
98
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,VIC,WA
Recruitment hospital [1] 0 0
GenesisCare North Shore - Sydney
Recruitment hospital [2] 0 0
ICON Cancer Centre South Brisbane - Brisbane
Recruitment hospital [3] 0 0
Southern Oncology Clinical Research Unit - Adelaide
Recruitment hospital [4] 0 0
Peninsula & South Eastern Haematology and Oncology Group - Frankston
Recruitment hospital [5] 0 0
Cabrini Health - Malvern
Recruitment hospital [6] 0 0
Linear Clinical Research - Perth
Recruitment postcode(s) [1] 0 0
2065 - Sydney
Recruitment postcode(s) [2] 0 0
4101 - Brisbane
Recruitment postcode(s) [3] 0 0
5042 - Adelaide
Recruitment postcode(s) [4] 0 0
- Frankston
Recruitment postcode(s) [5] 0 0
3144 - Malvern
Recruitment postcode(s) [6] 0 0
6009 - Perth
Recruitment outside Australia
Country [1] 0 0
Moldova, Republic of
State/province [1] 0 0
Chisinau
Country [2] 0 0
Singapore
State/province [2] 0 0
Singapore

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Hummingbird Bioscience
Address
Country
Other collaborator category [1] 0 0
Commercial sector/industry
Name [1] 0 0
Merck KGaA, Darmstadt, Germany
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Kon Yew Kwek, BMBCh, DPhil
Address 0 0
Country 0 0
Phone 0 0
+65 6979 5574
Fax 0 0
Email 0 0
k.y.kwek@hummingbirdbio.com
Contact person for scientific queries

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
No/undecided IPD sharing reason/comment


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.


Results not provided in https://clinicaltrials.gov/study/NCT05910827